Afuco™ Anti-MET ADCC Recombinant Antibody (Onartuzumab), ADCC Enhanced (CAT#: PABZ-155)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Human Antibody (Onartuzumab (OA5D5.v2)) is capable of binding to MET, expressed in CHO.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Onartuzumab functionally inhibits HGF/MET signaling.

Figure 1 Onartuzumab functionally inhibits HGF/MET signaling.

The relative inhibition of HGF binding (B), MET phosphorylation by KIRA in A549 cells treated with HGF (C), and cell proliferation in Ba/F3-huMET cells (D) is shown for chOA5D5, huOA5D5.v1, and huOA5D5.v2 [onartuzumab (MetMAb)]. (E) Onartuzumab inhibits HGF-dependent MET phosphorylation and downstream activation of GAB1, AKT, ERK1/2, and P70-S6 in a dose-dependent fashion but does not induce any MET signaling in the absence of HGF. (F) Onartuzumab inhibits HGF-dependent migration and wound closure in HGF-treated A549 cells with an IC₅₀ of 20 nM. All plots reflect group mean plus and minus the SEM (n = 3).

Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., ... & Santell, L. (2013). Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences, 110(32), E2987-E2996.

Figure 2 The one-armed 5D5 antibody and onartuzumab have prolonged exposure in mice and antitumor activity in HGF-dependent tumor models.

Figure 2 The one-armed 5D5 antibody and onartuzumab have prolonged exposure in mice and antitumor activity in HGF-dependent tumor models.

(A) The chOA5D5 and 5D5 Fab proteins were dosed at 5 mg/kg i.v. in nude mice (n = 5), and their serum concentrations were measured over a 2-wk period. The serum half-life for the 5D5 Fab was a few minutes versus 5.8 d for the chOA5D5 antibody. (B) Serum drawn from nude mice dosed in A at day 7 posttreatment was assessed via Western blot using anti-Fab antibodies in nonreduced (Left) or reduced (Right) conditions, demonstrating stability of chOA5D5 in vivo relative to the 5D5 Fab. (C) Nude mice (n = 10 per group) bearing s.c. U-87 MG xenograft tumors were treated with onartuzumab at doses between 1–60 mg/kg, given once via i.p. injection. Data are plotted as group mean tumor volumes, with SEM indicated. Overall tumor response rates were calculated based upon the combined number of partial responses (PRs) and complete regressions (CRs), defined as>50% or 100% drop in tumor volumes, respectively, at any time during the study, and were determined for each dose group to be as follows: 1 mg/kg, 5 PRs and 0 CRs; 3.75 mg/kg, 5 PRs and 0 CRs; 7.5 mg/kg, 90% (7 PRs and 2 CRs); 15 mg/kg, 100% (5 PRs and 5 CRs); 30 mg/kg, 70% (2 PRs and 5 CRs); and 60 mg/kg, 100% (6 PRs and 4 CRs).

Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., ... & Santell, L. (2013). Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences, 110(32), E2987-E2996.

Figure 3 The one-armed 5D5 antibody and onartuzumab have prolonged exposure in mice and antitumor activity in HGF-dependent tumor models.

Figure 3 The one-armed 5D5 antibody and onartuzumab have prolonged exposure in mice and antitumor activity in HGF-dependent tumor models.

(D) Immunoprecipitation–immunoblot analysis for p-MET (IP-MET, IB-pTyr) and total MET (IP-MET, IB-MET) from U-87 MG xenograft tumors from nude mice following treatment with 30 mg/kg, i.p., once at the indicated time points. (E) MRI evaluation of intracranial U-87 MG xenograft tumors (n = 10 per group) treated with vehicle (black circles), onartuzumab at doses of 7.5 mg/kg (purple triangles), 30 mg/kg (blue circles), 60 mg/kg (green squares), or 120 mg/kg (red diamonds), dosed i.p., once at pretreatment (P), 1 and 2 wk postdose. The mean starting tumor volume for the vehicle group is indicated by the dashed line. Group mean and SEM for each group is shown overlaying the individual animal tumor volumes. (F) Kaplan–Meier analysis for intracranial U-87 MG tumors treated with vehicle (black line) or onartuzumab at 7.5 mg/kg (purple line), 30 mg/kg (blue line), 60 mg/kg (green line), and 120 mg/kg (red line). The median survival for each group was as follows: vehicle, 21 d; 7.5 mg/kg, 37 d; 30 mg/kg, 52 d; 60 mg/kg, 53 d; 120 mg/kg, 51 d. (G) hHGFtg-C3H-SCID mice (n = 10 per group) bearing s.c. NCI-H596 xenograft tumors were treated with either vehicle (white circles) or onartuzumab dosed at 15 mg/kg (light blue diamonds), 30 mg/kg (medium blue squares), or 60 mg/kg mg/kg (dark blue stars). Growth of NCI-H596 in littermate C3H-SCID mice is shown (black circles). Data are shown as group mean tumor volumes, with SEM indicated. (H) Immunoprecipitation–immunoblot analysis for p-MET (IP-MET, IB-pTyr) and total Met (IP-MET, IB-MET) from NCI-H596 xenograft tumors from hHGFtg-C3H-SCID mice following treatment with 30 mg/kg, i.p., once at 0 and 72 h.

Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., ... & Santell, L. (2013). Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences, 110(32), E2987-E2996.

Figure 4 Affinity maturation of mouse 5D5 to generate onartuzumab

Figure 4 Affinity maturation of mouse 5D5 to generate onartuzumab

The on (kon) and off (koff) rates and affinity measurements (KD) are summarized for each clone.

Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., ... & Santell, L. (2013). Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences, 110(32), E2987-E2996.


Specifications

  • Immunogen
  • Human MET proto-oncogene, receptor tyrosine kinase
  • Host Species
  • Humanized
  • Derivation
  • Mouse
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Clone
  • Onartuzumab
  • Applications
  • ELISA, Neut
  • Conjugate
  • Unconjugated

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • MET; MET proto-oncogene, receptor tyrosine kinase; HGFR; AUTS9; RCCP2; c-Met; hepatocyte growth factor receptor; SF receptor; HGF receptor; HGF/SF receptor; proto-oncogene c-Met; scatter factor
    receptor; tyrosine-protein kinase Met; met proto-oncogene tyrosine kinase

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Onartuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Onartuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone Onartuzumab"

See other products for "MET"

Humanized Antibody

CAT Product Name Application Type
TAB-H24 Anti-Human MET Recombinant Antibody (Emibetuzumab) FuncS, IF, Neut, ELISA, FC, IP, WB IgG4 - kappa
TAB-0332CL Human Anti-MET Recombinant Antibody (TAB-0332CL) ELISA Humanized Antibody
TAB-026MZ Anti-Human MET Recombinant Antibody (73R009) WB Humanized antibody
TAB-0881CLV Human Anti-MET Recombinant Antibody (TAB-0881CLV) ELISA, FuncS Humanized IgG1
TAB-0883CLV Human Anti-MET Recombinant Antibody (TAB-0883CLV) ELISA, FuncS Humanized IgG1

Immunotoxin

CAT Product Name Application Type
AGTO-G049E Anti-MET immunotoxin (Fab)-PE Cytotoxicity assay, Function study

Chimeric Antibody

CAT Product Name Application Type
TAB-002MZ Anti-Human MET Recombinant Antibody (MvDN30) IHC, PET imaging Chimeric antibody (mouse/human)
TAB-002MZ-S(P) Anti-Human MET Recombinant Antibody scFv Fragment (MvDN30) IHC, PET imaging Chimeric antibody (mouse/human)
TAB-002MZ-F(E) Anti-Human MET Recombinant Antibody Fab Fragment (MvDN30) IHC, PET imaging Chimeric antibody (mouse/human)
TAB-0880CLV-F(E) Human Anti-MET Recombinant Antibody; Fab Fragment (TAB-0880CLV-F(E)) ELISA, FuncS Chimeric (mouse/human) Fab
TAB-0880CLV-S(P) Mouse Anti-MET Recombinant Antibody; scFv Fragment (TAB-0880CLV-S(P)) ELISA, FuncS Mouse scFv

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1726CQ Recombinant Rabbit Anti-MET Antibody (CBL1008) Neut IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H24 Afuco™ Anti-MET ADCC Recombinant Antibody (Emibetuzumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody

MHC Tetramer for Cancer

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABZ-155. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare